SCHEMBL7907192

SCHEMBL7907192

O=C(c1ccc(-c2ccc(F)cc2)cc1)N1CCC(C(=O)NC(c2ccccc2)C(F)(F)F)(c2ccc(F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 2/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
HSD11B1 P28845 2/20 0.45
ATM Q13315 1/20 0.43
FASN P49327 4/20 0.42
TSHR P16473 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
TACR1 P25103 1/20 0.40
PRKAA2 P54646 1/20 0.40
CCR1 P32246 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7900653 0.95 PTPN1 (0.42) SLC6A7KMT2AMEN1HSD11B1
SCHEMBL378790 0.85 TACR1 (0.47) SLC6A7KMT2AMEN1HSD11B1ATM
SCHEMBL378786 0.85 MEN1 (0.46) SLC6A7KMT2AMEN1HSD11B1ATM
SCHEMBL7910338 0.85 TACR1 (0.47) SLC6A7KMT2AMEN1HSD11B1ATM
SCHEMBL3714839 0.85 NPC1 (0.49) SLC6A7KMT2AMEN1HSD11B1ATM
SCHEMBL7908348 0.84 HSD11B1 (0.48) SLC6A7KMT2AMEN1HSD11B1ATM
SCHEMBL13092257 0.84 TSHR (0.50) SLC6A7KMT2AMEN1HSD11B1ATM
SCHEMBL7908720 0.83 CTSL (0.42) SLC6A7KMT2AMEN1ATMTSHR
SCHEMBL378834 0.83 TACR1 (0.48) SLC6A7KMT2AMEN1HSD11B1ATM
SCHEMBL378802 0.82 SLC6A9 (0.47) SLC6A7KMT2AMEN1HSD11B1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 SLC6A7 105/4885KMT2A 1488/4885MEN1 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.